Menu

What a Saturday!

| Robin Tuohy

Today, the 15 Support Group Leaders attending ASH with the IMF, were up at the crack of dawn—actually pre-dawn!  We were on the 5:45 am shuttle with a long and exciting day ahead of us. First stop:  We had a bird’s eye view (literally, see photo) of the IMF’s International Myeloma Working Group (IMWG) meeting.  […]

The Messiah

| Tom Swick

Here I am at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. The atmosphere is electric; the schedule is hectic. I am jet-lagged and sleep deprived. I promised to report all the news about immunotherapy and drugs in the pipeline. Over the first two days, I attended the International […]

Day 2 at ASH 2015

| Jack Aiello

Today’s events began with 7:30 am oral presentations on multiple myeloma therapies (excluding transplants, which came later in the afternoon). Highlights from the oral presentation during the day included: Revilmid®/VELCADE®/dexamethasone (RVd) + Panobinostat (Pano) for newly diagnosed patients (remember, Pano is only approved for relapsed patients) demonstrated a 46% near complete response (nCR) / complete […]

Global Advances in Multiple Myeloma Treatments

| Jim Barth

One thing that never seems to change with multiple myeloma is that nothing is black or white. There are more shades of gray than one can imagine. The more answers we get the more questions we have. That became quickly evident at our first major event on Friday, the IMF Symposium addressing Global Advances in […]